A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
Terminated · Phase 2 · NCT03248492
Conditions: Breast Cancer
At a glance
- Research payments reported, 2025
- $88,598
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 253
About the trial
- Sponsor
- Daiichi Sankyo (with AstraZeneca, Daiichi Sankyo Co., Ltd.)
- Tested
- DS-8201a (drug)
- Dates
- Started 2017-08-25; completion 2024-05-06
- Results posted
- Yes
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.
From ClinicalTrials.gov, last updated 2025-06-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $88,598 in research payments for this study in 2025 (8 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Charles H. Redfern, M.D. Hematology & Oncology · San Diego, CA
- Grace Wang, M.D. Hematology & Oncology · Miami, FL
- Jami Fukui, MD Medical Oncology · Honolulu, HI
- Ashley E. Frith, MD Medical Oncology · Saint Peters, MO
- Adam M. Brufsky, MD Specialist · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sharp Memorial Hospital $46,609
- West Kendall Baptist Hospital, FL $35,032
- Washington University $3,996
- UPMC Hillman Cancer Center $2,782
- Kaiser Foundation Hospital, HI $180
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.